Mark J. Foley - 30 Jun 2021 Form 4 Insider Report for Revance Therapeutics, Inc.

Role
CEO & President, Director
Signature
/s/ Gordon Ho, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
30 Jun 2021
Net transactions value
+$21,246
Form type
4
Filing time
02 Jul 2021, 19:52:10 UTC
Previous filing
07 Jun 2021
Next filing
15 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Other $21,246 +882 +0.11% $24.09 811,161 30 Jun 2021 Direct F1
holding RVNC Common Stock 70,913 30 Jun 2021 See footnote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired by Mr. Foley under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2021 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2 These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.